Reuters Share to FacebookShare to Twitter (3/18, Fick, Erman, Blenkinsop) reports that drugmakers are urging the Trump Administration and European Union officials to exempt medical goods from tariffs to avoid price increases on top-selling medicines like Novo Nordisk’s Wegovy and Merck’s Keytruda. Pharmaceutical industry sources indicate that tariffs could raise drug costs and hinder patient access. Some companies consider expanding US manufacturing, but seek tax breaks and regulatory changes. A senior executive from a European drugmaker emphasized the interconnected supply chains and potential harm to patient access. Novo Nordisk’s CEO Lars Fruergaard Jorgensen mentioned short-term effects from tariffs but plans to increase US production. The US government may face higher drug prices due to tariffs, according to Simon Baker from Redburn Atlantic.
Reuters Share to FacebookShare to Twitter (3/18, Santhosh, Singh, Satija, Fick) reports, “Widely used prescription medicines could get caught up in the Trump administration’s tariff trade wars and EU retaliation.” The article shows “a list of major prescription drugs whose ingredients or components are imported into the United States from the European Union, based on U.S. Food and Drug Administration import data from 2023 and 2024.”
Link: